Summary
Novo Nordisk provided updates on its next-generation obesity and diabetes drug, CagriSema, a potential successor to Ozempic and Wegovy.
CagriSema combines semaglutide with an amylin and calcitonin receptor agonist, promising enhanced weight loss and blood sugar regulation.
Early trials showed 15.6% weight loss over 32 weeks, and executives are optimistic larger trials could show up to 25% weight loss.
Results from late-stage trials are expected by mid-2025.
You must log in or register to comment.
And so, the cycle of minor, but copyrighted updates begins.
